Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.
Company profile
Ticker
QLGN
Exchange
Website
CEO
Andrew Ritter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RITTER PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Qualigen, Inc. • NanoSynex Ltd. ...
QLGN stock data
Latest filings (excl ownership)
8-K
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
30 May 24
NT 10-Q
Notice of late quarterly filing
14 May 24
S-1/A
IPO registration (amended)
3 May 24
424B3
Prospectus supplement
3 May 24
EFFECT
Notice of effectiveness
3 May 24
POS AM
Prospectus update (post-effective amendment)
30 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
10-K
2023 FY
Annual report
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Termination of a Material Definitive Agreement
28 Mar 24
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 401.80 k | 401.80 k | 401.80 k | 401.80 k | 401.80 k | |
Cash burn (monthly) | 263.38 k | 824.12 k | 1.13 mm | 1.89 mm | 858.69 k | |
Cash used (since last report) | 1.34 mm | 4.18 mm | 5.72 mm | 9.60 mm | 4.36 mm | |
Cash remaining | -935.42 k | -3.78 mm | -5.32 mm | -9.20 mm | -3.96 mm | |
Runway (months of cash) | -3.6 | -4.6 | -4.7 | -4.9 | -4.6 |
Institutional ownership, Q2 2023
57.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 6 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.28 bn |
Total shares | 3.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Alpha Capital Anstalt | 3.53 mm | $1.86 mm |
Meitav Dash Investments | 27.29 k | $3.21 bn |
BLK Blackrock | 25.84 k | $23.54 mm |
Geode Capital Management | 22.15 k | $20.18 mm |
STT State Street | 10.93 k | $9.96 mm |
HighMark Wealth Management | 8.01 k | $7.30 mm |
Tower Research Capital | 4.61 k | $4.20 mm |
UBS UBS Group AG - Registered Shares | 1.37 k | $1.25 mm |
USB U.S. Bancorp. | 824.00 | $751.00 k |
FMR | 512.00 | $466.00 k |